Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-09-13
2005-09-13
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093210, C424S450000, C435S320100, C536S023100
Reexamination Certificate
active
06943152
ABSTRACT:
The invention relates to immunogenic preparations or vaccines comprising, on the one hand, a plasmid encoding and expressing a gene from PCV, in particular selected from the group consisting of ORF1 of PCV-2, ORF2 of PCV-2, ORF1 of PCV-1 and ORF2 of PCV-1, and, on the other hand, an element capable of increasing the immune response directed against the product of expression of the gene, which can be a carbomer, a porcine cytokine, e.g. GM-CSF or a cationic lipid of formulain which R1is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R2is another aliphatic radical comprising from 2 to 3 carbon atoms, andt X is an hydroxyle ou amine group. The cationic lipid can be DMRIE, possibly coupled with DOPE.
REFERENCES:
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5106733 (1992-04-01), Baker et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5545412 (1996-08-01), Eppstein et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5719131 (1998-02-01), Harris et al.
patent: 5910488 (1999-06-01), Nabel et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6019980 (2000-02-01), Li et al.
patent: 6165493 (2000-12-01), Neurath et al.
patent: 6217883 (2001-04-01), Allan et al.
patent: 6287856 (2001-09-01), Poet et al.
patent: 6368601 (2002-04-01), Allan et al.
patent: 6391314 (2002-05-01), Allan et al.
patent: 6475779 (2002-11-01), Mathiowitz et al.
patent: 0 737 750 (1996-10-01), None
patent: WO 90 11092 (1990-10-01), None
patent: WO 92 05255 (1992-04-01), None
patent: WO 94 01133 (1994-01-01), None
patent: WO 94/21797 (1994-09-01), None
patent: WO 94/27435 (1994-12-01), None
patent: WO 96/34109 (1996-10-01), None
patent: WO 96 40945 (1996-12-01), None
patent: WO 98 40499 (1998-09-01), None
patent: WO 99/18214 (1999-04-01), None
patent: WO 99/29717 (1999-06-01), None
patent: WO 99/29871 (1999-06-01), None
patent: WO 00/01409 (2000-01-01), None
patent: WO 00 24428 (2000-05-01), None
patent: WO 00/77216 (2000-12-01), None
DMRIE structure, 2002.
Meehan et al. Characterization of novel circovirus dans associated with wasting syndromes in pigs Journal of General Virologt 1998 79, 2171-2179.
Restifo N P et al. The promises of nucleic acid vaccines, 2000, Gene Therpay, vol. 7, pp. 89-92.
Babiuk et al.; research tool or commercial reality, 2000, Veterinary immunologya nd immunopathology, nucleic acid vaccines, vol. 76,pp. 1-23.
Yokoyama et al. DNA immunization: Effects of vehicle and route of administration on theinduction of protective immunity., 1996, FEMS Immunology and medcal microbiology, vol. 14, pp. 221-230.
Meehan B. M.., et al., Charecterization of novel circovirus DNAs associated with wasting syndromes in pigs. 1998, Journal of General Virology, vol. 79, pp. 2171-2179.
Okada E. et al. Intranasal immunization of a DNA vaccine . . . immune responses against HIV-1 antigens. 1997, The Jouranl fo Immunology, vol. 159, pp. 3638-3647.
Felgner J.H. et al., Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. 1994, The journal of biological chemistry, vol. 269, pp. 2550-2561.
Mumford J. A. et al. Antigenicity and immunogenicity of equine imfleunza vacciens coantining a Carbomer adjuvant. 1994, vol. 112, pp. 421-437.
Miller, J.S. et al., “The nucleotide sequence of RNA-1 of Indian peanut clump furovirus” Arch. Virol. 141:2301-2312, 1996.
Parker SE et al., “Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo” Cancer Gene Therapy, May-Jun 1996.
Ishii N. et al., “Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1” AIDS Res Hum Retroviruses, Nov. 1, 1997.
Gregoriadis G. et al., “Liposome-mediated DNA vaccination” FEBS Letter, Feb. 3, 1997.
Behr, J.P., “Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy” Bioconjugate Chem. 5(5):382-389, 1994.
Xiang Z. et al., “Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines” Immunity, Feb. 1995.
S. Inumaru et al., Immunology and Cell Biology, (1995), vol. 73, pp. 474-476, XP-000946635, “cDNA Cloning of Porcine Granulocyte-Macrophage Colony-Stimulating Factor”.
Colin J. McInnes et al., Gene, 1991, pp. 275-279, XP-002148815, “Cloning and Expression of a cDNA Encoding Ovine Granulocyte-Macrophage Colony-Stimulating Factor”.
Nash RA et al., Blood 1991, XP 002133949, “Molecular cloning and in vivo evaluation of canine granulocyte-macrophage colony-stimulating factor”.
H.C.J. Ertl et al., Viral Immunology, vol. 9, 1996, pp. 1-9, “Genetic Immunization”.
John J. Donnelly et al., Journal of Immunological Methods, 1994, pp. 145-152 “Immunization with DNA”.
Gregory Gregoriadis, Pharmaceutical Research, 1998, vol. 15. No. 5, “Genetic vaccines: strategies for optimization”.
Diana Haddad et al., FEMS Immunology and Medical Microbiology 1997, pp. 193-202 Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice.
Carl J. Wheeler et al., 1996, pp. 1-11, XP 002035803, “Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes”.
Roberto Bei et al., Journal of Immunotherapy, 1998, pp. 159-169 “The Use of a Cationic Liposome Formulation (DOTAP) Mixed with a Recombinant Tumor-Associated Antigen to Induce Immune Responses and Protective Immunity in Mice”.
Yoshifumi Watanabe et al., J. Biochem. 116, 1994, pp. 1220-1226 “Highly Efficient Transfection into Primary Cultured Mouse Hepatocytes by Use of Cation-Liposomes: An Application for Immunization”.
Linda S. Klavinskis et al., J. Immunol 1999, “Intranasal Immunization with Plasmid DNA-Lipid Complexes Elicits Mucosal Immunity in the Femal Genital and Rectal Tracts”.
C. Somasundaram et al., Veterinary Immunology and Immunopathology 70, 1999, pp. 277-287 “Enhanced Protective Response and Immuno-Adjuvant Effects of Porcine GM-CSF on DNA Vaccination of Pigs against Aujeszky's Disease Virus”.
Jan Schultz et al., Intervirology 2000; vol. 43, pp. 197-217 “Update on Antiviral DNA Vaccine Research” (1998-2000).
Michael J. McCluskie et al., Molecular Medicine 5, 1999, pp. 287-300 “Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates”.
Jon A. Norman et al., Vaccine, vol. 15, No. 8, pp. 801-803, 1997, “ Development of Improved Vectors for DNA-Based Immunization and other Gene Therapy Applications”.
K. M. Ruitenberg et al., Vaccine, vol. 17, 1999, pp. 237-244, “DNA-Mediated Immunization with Glycoprotein D of Equine Herpesvirus 1 (EHV-1) in a Murine Model of EHV-1 Respiratory Infection”.
Jeong-Im Sin et al., Vaccine, vol. 15, 1997, pp. 1827-1833 “Protective Immunity Against Heterologous Challenge with Encephalomyocarditis Virus by VP1 DNA Vaccination: Effect of Coinjection with a Granulocyte-Macrophage Colony Stimulating Factor Gene”.
Cho et al., Enhanced cellular immunity of hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 17 (1999) pp. 1135-1144.
Meehan et al., Sequence of porcine circovirus DNA: affinities with plant circoviruses. Journal of General Virology, (1997) pp. 78, 221-227.
Accession No. XP-002153285 The nucleotide sequence of RNA-1 of Indian peanut clump furovirus. 1996, Archives of Virology vol. 141, pp 2301-2312.
Accession No. XP-002153286 Plasmid DNA gene therapy: Studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Ge
Audonnet Francis Jean-Christophe
Bublot Michel
Charreyre Catherine Elisabeth
Perez Jennifer Maria
Frommer & Lawrence & Haug LLP
Jarecki-Black Judy
Kowalski Thomas J.
Li Q. Janice
Merial
LandOfFree
DNA vaccine-PCV does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA vaccine-PCV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vaccine-PCV will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382106